Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | -- |
Average volume | -- |
---|---|
Shares outstanding | 80.97m |
Free float | 60.70m |
P/E (TTM) | -- |
Market cap | 130.36m EUR |
EPS (TTM) | -0.4215 EUR |
Data delayed at least 15 minutes.
More ▼
Press releases
- Innate Pharma Highlights Data From Its Innovative Oncology Portfolio Selected for the SITC Annual Meeting 2024
- Innate Pharma Announces Conference Call and Webcast for Third Quarter 2024 Results and Business Updates
- Innate Pharma Announces Its Participation in Upcoming Investor Conferences
- Innate Pharma Appoints Jonathan Dickinson as New Chief Executive Officer and Chairman of the Executive Board
- Innate Pharma to Host KOL Scientific Symposium on Immunotherapy in New York on October 3, 2024
- Innate Pharma Announces FDA Clearance of the IND for IPH4502, a Nectin-4 ADC to Be Developed in Solid Tumors
- Innate Pharma Reports First Half 2024 Business Update and Financial Results
- Innate Pharma SA: Monalizumab Data From NeoCOAST-2 Phase 2 Study in Early-Stage NSCLC Presented at the WCLC 2024
- Innate Pharma Announces Conference Call and Webcast for First Half 2024 Financial Results and Business Update
- Innate Pharma Announces Its Participation in the H.C. Wainwright 26th Annual Global Investment Conference
More ▼